Expert Video - Why is it important to have diversity in lung cancer clinical trials?
Diversity in lung cancer clinical trials is explained by Manish Patel, DO, Associate Professor of Medicine at the University of Minnesota. Diversity in testing lung cancer treatments helps treatments for lung cancer be relevant to diverse racial, ethnic, social, and economic groups.
Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about lung cancer which will help other patients, caregivers and families.
Please rate this content:
Other Modules:
Animation - Understanding Clinical Trials in Lung Cancer
Slide Show - Understanding Clinical Trials in Lung Cancer
1.
What is a clinical trial for lung cancer?
2.
Why are clinical trials needed for lung cancer?
3.
What are the different types and phases of lung cancer clinical trials?
4.
What is a clinical trial drug treatment protocol?
5.
Who can participate in a lung cancer clinical trial?
6.
How long will a lung cancer clinical trial typically last?
7.
How are lung cancer treatments approved, based on clinical trial outcomes?
8.
How do lung cancer patients find a clinical trial that is a good fit for them?
9.
Will I be randomized to receive one treatment versus another in a clinical trial?
10.
Why is it important to have diversity in lung cancer clinical trials?
11.
Why did you decide to join a lung cancer clinical trial?
12.
What was the clinical trial enrollment process like for you?
13.
What was your overall experience in the lung cancer clinical trial?
14.
What advice do you have for other people about participating in clinical trials for lung cancer?
15.
How did you use ClinicalTrials.gov to find a lung cancer clinical trial?
